TWENTY-YEAR COMPARATIVE ANALYSIS OF THE PREVALENCE, CLINICAL COURSE, AND PHARMACOLOGICAL TREATMENT OF CHRONIC HEART FAILURE: A LITERATURE REVIEW

Authors

  • Yuldasheva Feruza Master Student in Cardiology, Department of Faculty Therapy. Andijan state medical institute Author

Keywords:

Key words: Chronic heart failure, epidemiology; Risk factors; HFrEF; HFpEF; pharmacological therapy; SGLT2 inhibitors; Guideline-directed medical therapy (GDMT).

Abstract

Chronic heart failure (CHF) remains one of the leading causes of morbidity, mortality, and healthcare expenditures worldwide. Despite substantial advances in cardiovascular medicine, CHF continues to represent a major public health challenge due to the aging population, increasing prevalence of cardiovascular risk factors, and improved survival of patients with acute cardiovascular events. Over the past two decades, remarkable changes have occurred in the epidemiology, clinical presentation, diagnostic approaches, and pharmacological management of heart failure. Heart failure is a complex clinical syndrome characterized by the inability of the heart to provide adequate blood supply to meet the metabolic demands of the body. The syndrome results from structural and functional cardiac abnormalities that impair ventricular filling and/or ejection of blood. According to contemporary classifications, heart failure is categorized into heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), heart failure with preserved ejection fraction (HFpEF), and heart failure with improved ejection fraction (HFimpEF). This classification reflects the heterogeneity of the disease and has important therapeutic implications.

References

1.McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–3639.

2.Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145–e1032.

3.McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726.

4.Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129–2200.

5.Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart Disease and Stroke Statistics—2024 Update. Circulation. 2024.

6.Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7–11.

7.Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence. Lancet. 2018;391:572–580.

8.Roger VL. Epidemiology of Heart Failure. Circ Res. 2021;128:1421–1434.

9.Braunwald E. Heart Failure. JACC Heart Fail. 2013;1:1–20.

10.Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in heart failure: current evidence and future directions. Lancet. 2020.

Downloads

Published

2026-06-09